The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
Abstract
To assess the effect of dietary reduction of plasma cholesterol concentrations on coronary atherosclerosis, we set up a randomised, controlled, end-point-blinded trial based on quantitative image analysis of coronary angiograms in patients with angina or past myocardial infarction. Another intervention group received diet and cholestyramine, to determine the effect of a greater reduction in circulating cholesterol concentrations. 90 men with coronary heart disease (CHD), who had a mean (SD) plasma cholesterol of 7.23 (0.77) mmol/l were randomised to receive usual care (U, controls), dietary intervention (D), or diet plus cholestyramine (DC), with angiography at baseline and at 39 (SD 3.5) months. Mean plasma cholesterol during the trial period was 6.93 (U), 6.17 (D), and 5.56 (DC) mmol/l. The proportion of patients who showed overall progression of coronary narrowing was significantly reduced by both interventions (U 46%, D 15%, DC 12%), whereas the proportion who showed an increase in luminal diameter rose significantly (U 4%, D 38%, DC 33%). The mean absolute width of the coronary segments (MAWS) studied decreased by 0.201 mm in controls, increased by 0.003 mm in group D, and increased by 0.103 mm in group DC (p less than 0.05), with improvement also seen in the minimum width of segments, percentage diameter stenosis, and edge-irregularity index in intervention groups. The change in MAWS was independently and significantly correlated with LDL cholesterol concentration and L…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only 3 studies were on stroke (20), (23), (25), and the incidence of stroke was almost zero in 2 of those studies (23), (25).”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [23]
In the citing paper
“Seven trials exhibited some concerns (15), (19), (20), (21), (22), (24), (25), and 2 trials exhibited a high risk of bias (18), (23).”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [23]
Citations
Cites
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Can lifestyle changes reverse coronary heart disease?
Ornish, D., Brown, S. E., Billings, J. H., Scherwitz, L. W., Armstrong, W. T., Ports, T. A., McLanahan, S. M., Kirkeeide, R. L., Gould, K. L., & Brand, R. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91656-u · Cited by 2,110
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Research works printed but not linked: 28
- Study Group, 1988, The treatment of hyperlipidaemia in adults. Recommendations of the European Atherosclerosis Society, Eur Heart J, 8, 277
- Duffield, 1983, Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis, Lancet, ii, 639, 10.1016/S0140-6736(83)92527-8 · DOI
- Amtzenius, 1985, Diet, lipoproteins, and the progression of coronary atherosclerosis, N Engl J Med, 312, 805, 10.1056/NEJM198503283121301 · DOI
- Blankenhom, 1990, The influence of diet on the appearance of new lesions in human coronary arteries, JAMA, 263, 1646, 10.1001/jama.263.12.1646 · DOI
- Lewis, 1974, Serum lipoprotein abnormalities in patients with ischaemic heart disease: comparisons with a control population, Br Med J, iii, 489, 10.1136/bmj.3.5929.489 · DOI
- Campeau, 1976, Grading of angina pectoris, Circulation, 54, 522, 10.1161/circ.54.3.947585 · DOI
- Austen, 1975, AHA committee report. A reporting system on patients evaluated for coronary artery disease, Circulation, 51, 7, 10.1161/01.CIR.51.4.5 · DOI
- Colchester, 1983, Measurement of vessel calibre and volume blood flow by dynamic quantitative digital angiography: an initial application showing variation of cerebral artery diameter with PaCO2, J Cerebr Blood Flow Metab, 3, S640
- Jnh Brunt, Design, implementation, validation and use of a system for quantitative coronary cineangiography ((Rotterdam, 1989) 32 (abstr)), Third international symposium on coronary arteriography.
- Brown, 1982, Arteriographic assessment of coronary atherosclerosis, Arteriosclerosis, 2, 2, 10.1161/01.ATV.2.1.2 · DOI
- Crawford, 1977, Computer densitometry for angiographic assessment of arterial cholesterol content and gross pathology in human atherosclerosis, J Lab Clin Med, 89, 378
- Blankenhorn, 1991, Effects of colestipolniacin therapy on human femoral atherosclerosis, Circulation, 83, 438, 10.1161/01.CIR.83.2.438 · DOI
- Blankenhorn, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.257.23.3233 · DOI
- Kane, 1990, Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimens, JAMA, 264, 1007, 10.1001/jama.264.23.3007 · DOI
- Wissler, 1976, Studies of regression of advanced atherosclerosis in experimental animals and men, Ann NY Acad Sci, 275, 363, 10.1111/j.1749-6632.1976.tb43368.x · DOI
- La Ville, 1989, Primary prevention of atherosclerosis by lovastatin in a genetically hyperlipidaemic rabbit strain, Atherosclerosis, 78, 205, 10.1016/0021-9150(89)90224-4 · DOI
- Habib, 1984, Atherosclerosis impairs endothelium-dependent arterial relaxation, Circulation, 70, 123
- Vita, 1990, Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease, Circulation, 81, 491, 10.1161/01.CIR.81.2.491 · DOI
- Harrison, 1987, Restoration of endothelium-dependent arterial relaxation by dietary treatment of atherosclerosis, Circulation, 80, 1808
- Vartiainen, 1947, Arteriosclerosis and wartime, Ann Med Intern Fen, 34, 705
- Wilens, 1947, The resorption of arterial atheromatous deposits in wasting disease, Am J Pathol, 33, 793
- Lewis, 1981, Towards an improved lipid-lowering diet: additive effects of changes in nutrient intake, Lancet, ii, 1310, 10.1016/S0140-6736(81)91339-8 · DOI
- Choudhury, 1984, A multifactorial diet in the management of hyperlipidaemia, Atherosclerosis, 50, 93, 10.1016/0021-9150(84)90011-X · DOI
- Lipid Research Clinics Program, 1984, The Lipid Research Clinics coronary primary prevention trial results, I. Reduction in incidence of coronary heart disease, JAMA, 251, 351, 10.1001/jama.251.3.351 · DOI · Paper page
- Brensike, 1984, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study, Circulation, 69, 313, 10.1161/01.CIR.69.2.313 · DOI
- Ambrose, 1988, Angiographic progression of coronary artery disease and the development of myocardial infarction, J Am Coll Cardiol, 12, 56, 10.1016/0735-1097(88)90356-7 · DOI
- Hackett, 1989, Coronary stenoses before and after acute myocardial infarction, Am J Cardiol, 63, 1517, 10.1016/0002-9149(89)90018-0 · DOI
- Roussouw, 1990, The value of lowering cholesterol after myocardial infarction, N Engl J Med, 323, 1112, 10.1056/NEJM199010183231606 · DOI
Cited by
Sorted by citations
Items 601–700 of 765
Non-pharmacological modification of cardiac risk factors: part 2. The role of diet
Martin, U., & Eagles, C. J. (1997) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1997.tb00003.x · Cited by 3
Lièvre, M., Finet, G., & Maupas, J. (1997) · International Journal of Cardiac Imaging · doi:10.1023/a:1005709828504 · Cited by 3
“Mean lumen diameter, which integrates the lumen diameter over the length of an arterial segment, is a preferred endpoint in some recent studies [4, 5].”
BackgroundLessons learned from angiographic coronary atherosclerosis trials
Jukema, J. W., Bruschke, A. V. G., & Reiber, J. H. C. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-0291-6_9 · Cited by 4
Villecco, A., de Aloysio, D., Foderaro, S., Camillo, T. D., Iervese, T., & Camillo, G. D. (1995) · Current Therapeutic Research · doi:10.1016/0011-393x(95)85085-6 · Cited by 3
Rubba, P., & Faccenda, F. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.15.8262334 · Cited by 3
Jacob, B., Richter, W., & Schwandt, P. (1993) · Clinical Investigation · doi:10.1007/bf00185602 · Cited by 3
“0 appears desirable for the treatment and prevention of atherosclerosis [13].”
BackgroundRole of dietary spices in modulating inflammation and oxidative stress
Oh, E. S., Petersen, K. H., Kris‐Etherton, P. M., & Rogers, C. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823482-2.00005-4 · Cited by 2
Resource Utilisation in the Management of Dyslipidaemia
Szucs, T. D. (1998) · PharmacoEconomics · doi:10.2165/00019053-199814003-00002 · Cited by 7
“tant effects on lipid levels and on angiographic parameters of CHD,[48,49] while others suggest that dietary changes are ineffective.”
BackgroundInfluentialHochholzer, W., & Giugliano, R. P. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0290-8 · Cited by 3
Diet Controversies in Lipid Therapy
Winston, M. C., Jeor, S. S., & Ashley, J. M. (2000) · The Journal of Cardiovascular Nursing · doi:10.1097/00005082-200001000-00005 · Cited by 4
Multiple Risk Factors in Cardiovascular Disease
Gotto, A., Lenfant, C., Paoletti, R., Catapano, A., Jackson, A. S., & Lorenzini, G. (1998) · Medical Science Symposia Series · doi:10.1007/978-94-011-5022-4 · Cited by 3
“A Finnish population-based study also revealed an independent association of fibrinogen with carotid arterial wall thickness in middle-aged subjects [14].”
BackgroundInfluentialBath, P., Blann, A., & Watts, G. F. (1994) · Platelets · doi:10.3109/09537109409005525 · Cited by 3
Self-citationNeurohumoral Regulation of Coronary Flow
van Gilst, W. V., & Kong, L. I. (1993) · Developments in Cardiovascular Medicine · doi:10.1007/978-94-011-1900-9 · Cited by 3
(2025) · JMA Journal · doi:10.31662/jmaj.2024-0324 · Cited by 2
“Only 3 studies were on stroke (20), (23), (25) , and the incidence of stroke was almost zero in 2 of those studies (23), (25) .”
InfluentialDayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2
Further response from Hoenselaar
Hoenselaar, R. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000402 · Cited by 5
Community nutrition education for people with coronary heart disease--who attends?
Elliott, H. (2010) · Australian Journal of Public Health · doi:10.1111/j.1753-6405.1995.tb00375.x · Cited by 2
Guyton, J. R., & Goldberg, A. C. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50027-5 · Cited by 8
Gene-activators prevent and regress atherosclerosis and reduce mortality.
Luoma, P. (2009) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152509789541918 · Cited by 2
Stauffer, B. L., Kushner, E. J., Wulfman, T., Zeller, T., Sobus, R. D., & Westby, C. M. (2008) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2008.00071.x · Cited by 2
Expert commentary: gastrointestinally active lipid-lowering drug safety.
Toth, P. (2007) · American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.023 · Cited by 2
Sasaki, H., Kanai, S., Oyama, T., Miyashita, Y., & Shirai, K. (2005) · Journal of atherosclerosis and thrombosis · doi:10.5551/jat.12.218 · Cited by 2
Effects of dietary modification to reduce vascular risks and treatment of obesity
Stone, N. J., & Kushner, R. F. (2003) · Cardiology Clinics · doi:10.1016/s0733-8651(03)00057-2 · Cited by 3
Niebauer, J., & Schuler, G. (2001) · Zeitschrift für Kardiologie · doi:10.1007/s003920170078 · Cited by 4
Cowie, M. (2000) · Hospital Medicine · doi:10.12968/hosp.2000.61.11.1465 · Cited by 2
Efficacy of Two Lipid-Lowering Treatments on Quantitative Coronary Angiographic Endpoints
Mack, W. J., Xiang, M., Shircore, A. M., Selzer, R. H., Hodis, H. N., & Azen, S. P. (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007816300468 · Cited by 2
Current concepts in secondary prevention after acute myocardial infarction
Mehta, R. H., Bossone, E., & Eagle, K. A. (2000) · Herz · doi:10.1007/bf03044123 · Cited by 8
Low-Dose Simvastatin in the Treatment of Mild to Moderate Hypercholesterolaemia
Lepre, F., Nestel, P. J., Clifton, P. M., Lloyd, B., & Morgan, T. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199713050-00002 · Cited by 2
Arterial thrombosis for the clinician. Pathobiology and emerging concepts.
Becker, R. C. (1995) · Cardiology Clinics · doi:10.1016/s0733-8651(18)30030-4 · Cited by 2
Effect of ciprofibrate in patients with primary hypercholesterolemia: a 6-year pilot study
da Col, P., Bordin, P., Fonda, M., Valenti, M., Fisicaro, M., Tonizzo, M., & Cattin, L. (1995) · doi:10.1016/0011-393x(95)85083-x · Cited by 2
Rationale for Cholesterollowering Strategies
Grundy, S. M., & Friedman, D. E. (1995) · Current Problems in Cardiology · doi:10.1016/s0146-2806(06)80016-2 · Cited by 1
A ONE‐YEAR MULTICENTRE STUDY OF SIMVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
The UK and Eire Simvastatin Study Group (1994) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1994.tb09821.x · Cited by 2
Can any agreement be reached on cholesterol lowering?
Durrington, P. (1994) · British heart journal · doi:10.1136/hrt.71.2.125 · Cited by 2
Essential Fatty Acids and Vascular Disease
Fehily, A. (1993) · doi:10.1177/1358863x9300400403 · Cited by 2
Frequency of citation and outcome of cholesterol lowering trials.
Game, F., & Neary, R. (1992) · British medical journal · doi:10.1136/bmj.305.6850.421-a · Cited by 2
Effect of Dietary Fatty Acid Intake on Cardiovascular Disease
Joris, P. J., & Mensink, R. P. (2015) · Elsevier eBooks · doi:10.1016/b978-1-78242-247-1.00007-7 · Cited by 3
Use of Combination Statin and Bile Acid Sequestrant Therapy to Treat Dyslipidemia
Toth, P. P., Nikolić, D., Rizz, M., Rysz, J., & Banach, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_1 · Cited by 2
Chapter 11 A cerebrovascular perspective of atherosclerosis
Nichols, F. T., Shaltoni, H. M., & Yatsu, F. M. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(08)01911-8 · Cited by 2
Mirabelli, M. H., & Shehab, R. (2008) · Elsevier eBooks · doi:10.1016/b978-141603000-3.10019-x · Cited by 2
Primary Prevention of Ischemic Heart Disease
Meadows, J. L., Danik, J. S., & Albert, M. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50015-2 · Cited by 4
Myocardial Perfusion Imaging with PET
Carli, M. F. D., & Dorbala, S. (2007) · Springer eBooks · doi:10.1007/978-0-387-38295-1_11 · Cited by 2
Sakai, A., Hirayama, A., Adachi, T., Nanto, S., Hori, M., Inoue, M., Kamada, T., & Kodama, K. (2005) · Heart and Vessels · doi:10.1007/bf01746206 · Cited by 2
“Recent clinical studies have clearly demonstrated that cholesterol-lowering therapy induces regression of coronary atherosclerosis and markedly reduces the incidence of cardiovascular events [28-31].”
BackgroundFrishman, W. H., Cheng-Lai, A., & Chen, J. Y. (2000) · doi:10.1007/978-1-4615-6767-7_12 · Cited by 3
Krachler, M., Lindschinger, M., Watzinger, N., Eber, B., & Wallner, S. (2000) · doi:10.1002/(sici)1520-670x(2000)13:2 · Cited by 2
Lisspers, J., Söderman, E., Sundin, Ö., & Nygren, Å. (1999) · Scandinavian Journal of Behaviour Therapy · doi:10.1080/028457199440089 · Cited by 2
Aggressive medical therapy for the prevention and treatment of coronary artery disease.
Malloy, M., & Kane, J. (1997) · Advances in internal medicine · doi:10.1016/s0011-5029(98)90000-1 · Cited by 2
Reversal of Atherosclerosis with Therapy: Update of Coronary Angiographic Trials
Hodis, H. N. (1996) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60279-3 · Cited by 1
The Reversibility of Obesity, Diabetes, Hyperlipidemia, and Coronary Heart Disease
Anderson, J. W., & Akanji, A. O. (1994) · Humana Press eBooks · doi:10.1007/978-1-4684-8136-5_10 · Cited by 3
Xu, Y., Ding, N., Hua, R., Wu, Y., Li, T., & Yuan, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1730403 · Cited by 1
Sayed, A., Swanson, J., Kip, K., Jesrani, E. K., Reis, S. E., & Saeed, A. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.003 · Cited by 1
The efficacy of fish oil in preventing coronary heart disease
Wu, G., Geng, H., Jiang, Y., Song, W., Zhu, X., & Zhu, X. (2021) · Medicine · doi:10.1097/md.0000000000027253 · Cited by 12
“…1989 [18] Lancet RCTs Europe Single-blind 2133 127 1 0 0 180 1 0 1 Nye, 1990 [19] Aust N Z J Med RCTs Oceania Single-blind 73 5 0 1 1 11 0 1 1 Watts, 1992 [20] Lancet RCTs Europe Single-blind 110 2 0 0 1 5 0 0 2 Kaul, 1992 [21] Int J Cardiol RCTs Asia Single-blind 107 26 1 1 2 16 1 1 3…”
Dietary Lipids and Physiological Function
Kitts, D. (2020) · Bailey's Industrial Oil and Fat Products · doi:10.1002/047167849x.bio105 · Cited by 1
Non-Newtonian pulsatile blood flow dynamics around a Y-junction
Bhowmick, D., Hasan, M. T., & Hasan, A. B. M. T. (2019) · 8TH BSME INTERNATIONAL CONFERENCE ON THERMAL ENGINEERING · doi:10.1063/1.5115936 · Cited by 1
C., S. (2019) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v7i4.154 · Cited by 1
Defining an Overdue Requiem for Palliative Cardiovascular Medicine
Esselstyn, C. B. (2016) · American Journal of Lifestyle Medicine · doi:10.1177/1559827616638647
Zamora, D., Boonseng, Leelarthaepin, Ringel, A., Davis, J. M., & Hibbeln, J. (2013) · British medical journal · doi:10.1136/bmj.f903 · Cited by 1
Evolution of the Lipid Clinic, 1968–2008
Lewis, B. (2011) · doi:10.1002/9781444318456.ch32 · Cited by 1
Self-citationSurampudi, P. N., Nagireddy, P., & Fonseca, V. (2009) · Therapy · doi:10.2217/thy.09.17 · Cited by 1
Statins and Plaque Stabilization
Miller, M. I., & Vogel, R. (2004) · doi:10.3109/9780203025673-25 · Cited by 1
Nutrition and Heart-Related Diseases
Olken, M. H., & Howell, J. D. (2000) · Cambridge University Press eBooks · doi:10.1017/chol9780521402149.120 · Cited by 1
Lipids--how low do you go: plaque regression and passivation.
Pradka, L. R. (2000) · Journal of Cardiovascular Nursing · doi:10.1097/00005082-200010000-00005 · Cited by 1
Müller, M., Wiechmann, M., Helms, C., Wulff, C., & Kolenda, K. (2000) · Zeitschrift für Kardiologie · doi:10.1007/s003920050511 · Cited by 1
Park, J., Oh, S., Kim, K., Ahn, S.-H., & Kim, Y. K. (1999) · doi:10.4070/kcj.1999.29.3.266 · Cited by 1
Novazzi, J. P., PintoLdo, E., Auriemo, C., & Tl, M. (1998) · doi:10.1590/s0066-782x1998000300003 · Cited by 1
LDL-cholesterol lowering and atherosclerosis - clinical benefit and possible mechanisms: an update
Kroon, A. A., & Stalenhoef, A. F. H. (1997) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00031-4 · Cited by 1
Sandison, A., & Taylor, P. (1997) · International journal of clinical practice · doi:10.1111/j.1742-1241.1997.tb11467.x · Cited by 1
Control of Risk Factors in Atherosclerosis POSCH Report a
Buchwald, H., & Campos, C. T. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb17331.x · Cited by 1
Sniderman, A. D. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90135-n · Cited by 1
Treatment of and Screening for Hyperlipidemia
Ornish, D., & Brown, S. E. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310073291515 · Cited by 1
Coronary atherosclerosis on angiography--progress or regress, and why?
Ravnskov, U. (1993) · Circulation · doi:10.1161/01.cir.88.3.1358 · Cited by 1
Reversing coronary atherosclerosis
Kahn, J. K. (1993) · Postgraduate Medicine · doi:10.1080/00325481.1993.11945678 · Cited by 1
Bile Acid Sequestrants: Risk–Benefits and Role in Treating Dyslipidemias
Ganda, O., & Garg, A. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_27 · Cited by 1
Approach document for dyslipidemia. Spanish Society of Atherosclerosis (part II)
Núñez-Cortés, J., Alegrı́a, E., Walther, L. A., Gimilio, J. A., Rallo, C. L., Morató, T. M., Prieto, J., Montoya, J., & Sala, X. P. (2012) · doi:10.1016/j.arteri.2011.09.005 · Cited by 1
Bewegungstherapie bei koronarer Herzkrankheit
Niederseer, D., & Niebauer, J. (2010) · Springer eBooks · doi:10.1007/978-3-642-01332-4_10 · Cited by 6
Citkowitz, E., & Herbert, P. N. (1999) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-5007-5_3 · Cited by 2
Usefulness of Intravascular Ultrasound for Detecting Atherosclerosis Progression Or Regression
Hong, M. K., Leon, M. B., & Mintz, G. S. (1997) · Developments in cardiovascular medicine · doi:10.1007/978-1-4615-6287-0_10 · Cited by 1
Gene therapy for the vulnerable atherosclerotic plaque
Feldman, L. J., & Isner, J. M. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-94-009-1577-0_24 · Cited by 2
Jones, P. H. (1996) · Endocrine Practice · doi:10.4158/ep.2.1.30 · Cited by 1
Assessment of Myocardial Perfusion with 13N-Ammonia or 82RB
Schwaiger, M., Muzik, O., & Hutchins, G. D. (1996) · Developments in cardiovascular medicine · doi:10.1007/978-1-4613-1233-8_6 · Cited by 1
Angiographic Trials on Progression and Regression of Atherosclerosis by Plasma Lipid Reduction
Lewis, B. (1996) · Medical science symposia series · doi:10.1007/978-94-009-0311-1_14
Self-citationChennell, A., Sullivan, D., Penberthy, L., & Hensley, W. (1994) · Pathology (Sydney) · doi:10.1080/00313029400169202 · Cited by 1
Roik, N. V., Belyakova, L. A., & Dziazko, M. O. (2022) · Applied Nanoscience · doi:10.1007/s13204-022-02677-2
“For this purpose, oral nonabsorbable anion-exchange resins, such as Cholestyramine, Colestipol, and Colesevelam, are used in clinical practice for last decades (Cashin-Hemphill et al. 1991; Watts et al. 1992; Insull 2006).”
MethodEconomic Challenge of Cardiovascular Disease
Martinez, T. L., Vale, A., Saldanha, A., Gasparoto, A., Pantoja, A. P., & Fonseca, H. A. R. D. (2019) · Online Journal of Cardiovascular Research · doi:10.33552/ojcr.2019.03.000558
“Page 2 of 4 the risk of new myocardial infarction is increased by 3 to 6 times and, within 5 years, the risk of any CAD event is up to 80% [5].”
BackgroundAtherosclerotic Plaque Regression: Cause of Bypass Graft Oclussion
Lucia, C., Anamaria, A., Valentin, C., Andrei, R., & Irinel, P. (2018) · doi:10.2478/arsm-2018-0005
Kim, Y., Jung, M., & Kim, C. (2016) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2016.5.1.79
Fettarme Kost oder Mittelmeerdiät
Zyriax, B. (2015) · CardioVasc · doi:10.1007/s15027-015-0776-8
Hilleman, D., Pincus, K., Wadibia, E., Stading, J., Woodruff, M. P., & Lucas, B. (2015) · doi:10.18553/jmcp.1995.1.3.188
The Role of Nutrition in Secondary Prevention of Coronary Artery Disease
Hill, A. M., Roussell, M. A., & Kris‐Etherton, P. M. (2011) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-011-0188-y
On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
Lewis, B., Watts, G., & Sullivan, D. (2010) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2010.01.002
Self-citationOn the road to better dyslipidemia outcomes.
Hughes, S. (2009) · The Nurse Practitioner · doi:10.1097/01.npr.0000345263.05795.40
CVD - Putting the portfolio diet into practice
Frcgp, S. J. (2008) · Independent Nurse · doi:10.12968/indn.2008.3.10.76137
Unhealthy lifestyle, statins and the secondary prevention of cardiovascular disease
Mascitelli, L., & Pezzetta, F. (2007) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01379.x
Cholesterol lowering in patients with CHD and metabolic syndrome.
Mascitelli, L., & Pezzetta, F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60022-1
Women’s Health Initiative Results Leave No Doubt Diet Is Important
van Horn, L. V. (2006) · doi:10.1016/j.jada.2006.04.011
Controversia terapéutica: clopidogrel y estatinas
Meco, J., & Pintó, X. (2006) · doi:10.1016/s0214-9168(06)73705-6
Primary prevention of ischaemic heart disease
Hobbs, R. F. (2006) · Medicine · doi:10.1383/medc.2006.34.5.178
Historia natural de la arteriosclerosis. Expresividad cl?nica. Complicaciones agudas y cr?nicas
Torres-Grate, R., lvarez-Rodrguez, E., & Manuel, E. C. (2005) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(05)73755-3
Statins and Inhibition of Atherosclerosis: Human Studies
Sinha, A. K., Singh, B. M., & Mehta, J. L. (2004) · Elsevier eBooks · doi:10.1016/b978-0-7216-0380-3.50008-9 · Cited by 2
Alimentos para la prevención cardiovascular: ¿qué es efectivo y qué no lo es?
Ordóñez‐Llanos, J. (2002) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(02)78839-6
Metadata
- Authors
- Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I.
- Affiliations
- St Thomas' Hospital (GB)
- University of Manchester (GB)
- University of Otago (NZ)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1992-03
- Volume
- 339
- Issue
- 8793
- Pages
- 563-569
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2132942256
- Cited by
- 843
- References
- 34
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 4 · 2021: 5 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 10 · 2013: 15 · 2012: 11
- FWCI
- 103.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- coronary artery disease, lipid-lowering diet, cholestyramine, dietary cholesterol reduction, coronary atherosclerosis regression, coronary angiography, coronary lumen diameter, LDL cholesterol, LDL/HDL ratio, cardiovascular events, hypercholesterolemia
- MeSH terms
- Angina Pectoris, Cholesterol, Cholestyramine Resin, Combined Modality Therapy, Coronary Artery Disease, Coronary Disease, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Remission Induction, Treatment Outcome, Coronary Angiography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review